Sclerostin is a key regulator of Wnt signalling in bone and cartilage pathology in osteoarthritis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1026511

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Osteoarthritis (OA) is the most widespread bone and joint problem in Australia with has enormous social and economic consequences. We have identified Sclerostin (SOST) as a key regulator of the signalling pathway that drives the increase in production of bone and the erosion of cartilage in joints that are the hallmark of OA. The aims of the present project are to determine the effect altering SOST activity on the initiation and progression of OA.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $590,945.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Rheumatology and Arthritis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Wnt signalling | bone remodelling | cartilage damage | osteoarthritis | therapy

Related Links